Literature DB >> 26969086

A distinct plasmablast and naïve B-cell phenotype in primary immune thrombocytopenia.

Shaun M Flint1, Adele Gibson2, Geoff Lucas3, Raghava Nandigam4, Louise Taylor4, Drew Provan4, Adrian C Newland5, Caroline O Savage2, Robert B Henderson6.   

Abstract

Primary immune thrombocytopenia is an autoimmune disorder in which platelet destruction is a consequence of both B- and T-cell dysregulation. Flow cytometry was used to further characterize the B- and T-cell compartments in a cross-sectional cohort of 26 immune thrombocytopenia patients including antiplatelet antibody positive (n=14) and negative (n=12) patients exposed to a range of therapies, and a cohort of matched healthy volunteers. Markers for B-cell activating factor and its receptors, relevant B-cell activation markers (CD95 and CD21) and markers for CD4(+) T-cell subsets, including circulating T-follicular helper-like cells, were included. Our results indicate that an expanded population of CD95(+) naïve B cells correlated with disease activity in immune thrombocytopenia patients regardless of treatment status. A population of CD21-naïve B cells was specifically expanded in autoantibody-positive immune thrombocytopenia patients. Furthermore, the B-cell maturation antigen, a receptor for B-cell activating factor, was consistently and strongly up-regulated on plasmablasts from immune thrombocytopenia patients. These observations have parallels in other autoantibody-mediated diseases and suggest that loss of peripheral tolerance in naïve B cells may be an important component of immune thrombocytopenia pathogenesis. Moreover, the B-cell maturation antigen represents a potential target for plasma cell directed therapies in immune thrombocytopenia. Copyright© Ferrata Storti Foundation.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26969086      PMCID: PMC5013956          DOI: 10.3324/haematol.2015.137273

Source DB:  PubMed          Journal:  Haematologica        ISSN: 0390-6078            Impact factor:   9.941


  32 in total

1.  Expressions of BAFF/BAFF receptors and their correlation with disease activity in Chinese SLE patients.

Authors:  L D Zhao; Y Li; M F Smith; J S Wang; W Zhang; F L Tang; X P Tian; H Y Wang; F C Zhang; D N Ba; W He; X Zhang
Journal:  Lupus       Date:  2010-11       Impact factor: 2.911

Review 2.  Mycophenolate mofetil: effects on cellular immune subsets, infectious complications, and antimicrobial activity.

Authors:  M L Ritter; L Pirofski
Journal:  Transpl Infect Dis       Date:  2009-05-26       Impact factor: 2.228

3.  Increase of B cell-activating factor of the TNF family (BAFF) after rituximab treatment: insights into a new regulating system of BAFF production.

Authors:  Frédéric Lavie; Corinne Miceli-Richard; Marc Ittah; Jérémie Sellam; Jacques-Eric Gottenberg; Xavier Mariette
Journal:  Ann Rheum Dis       Date:  2006-10-13       Impact factor: 19.103

4.  Similarities between known antiplatelet antibodies and the factor responsible for thrombocytopenia in idiopathic purpura. Physiologic, serologic and isotopic studies.

Authors:  N R Shulman; V J Marder; R S Weinrach
Journal:  Ann N Y Acad Sci       Date:  1965-06-30       Impact factor: 5.691

5.  Splenic TFH expansion participates in B-cell differentiation and antiplatelet-antibody production during immune thrombocytopenia.

Authors:  Sylvain Audia; Marzia Rossato; Kim Santegoets; Sanne Spijkers; Catharina Wichers; Cornelis Bekker; Andries Bloem; Louis Boon; Thijs Flinsenberg; Ewoud Compeer; Theo van den Broek; Olivier Facy; Pablo Ortega-Deballon; Sabine Berthier; Vanessa Leguy-Seguin; Laurent Martin; Marion Ciudad; Maxime Samson; Malika Trad; Bernard Lorcerie; Nona Janikashvili; Philippe Saas; Bernard Bonnotte; Timothy R D J Radstake
Journal:  Blood       Date:  2014-09-16       Impact factor: 22.113

6.  Long-term clinical outcomes of patients with primary chronic immune thrombocytopenia: a Danish population-based cohort study.

Authors:  Mette Nørgaard; Annette Ø Jensen; Malene C Engebjerg; Dóra K Farkas; Reimar W Thomsen; Steven Cha; Sean Zhao; Henrik T Sørensen
Journal:  Blood       Date:  2011-01-24       Impact factor: 22.113

7.  Circulating CD21low B cells in common variable immunodeficiency resemble tissue homing, innate-like B cells.

Authors:  Mirzokhid Rakhmanov; Baerbel Keller; Sylvia Gutenberger; Christian Foerster; Manfred Hoenig; Gertjan Driessen; Mirjam van der Burg; Jacques J van Dongen; Elisabeth Wiech; Marcella Visentini; Isabella Quinti; Antje Prasse; Nadine Voelxen; Ulrich Salzer; Sigune Goldacker; Paul Fisch; Hermann Eibel; Klaus Schwarz; Hans-Hartmut Peter; Klaus Warnatz
Journal:  Proc Natl Acad Sci U S A       Date:  2009-07-29       Impact factor: 11.205

8.  High-level serum B-cell activating factor and promoter polymorphisms in patients with idiopathic thrombocytopenic purpura.

Authors:  Florian Emmerich; Gürkan Bal; Alaa Barakat; Julian Milz; Caroline Mühle; Lorena Martinez-Gamboa; Thomas Dörner; Abdulgabar Salama
Journal:  Br J Haematol       Date:  2006-11-30       Impact factor: 6.998

9.  Anergic responses characterize a large fraction of human autoreactive naive B cells expressing low levels of surface IgM.

Authors:  Tâm D Quách; Nataly Manjarrez-Orduño; Diana G Adlowitz; Lin Silver; Hongmei Yang; Chungwen Wei; Eric C B Milner; Iñaki Sanz
Journal:  J Immunol       Date:  2011-03-11       Impact factor: 5.422

10.  T-cell-mediated cytotoxicity toward platelets in chronic idiopathic thrombocytopenic purpura.

Authors:  Bob Olsson; Per-Ola Andersson; Margareta Jernås; Stefan Jacobsson; Björn Carlsson; Lena M S Carlsson; Hans Wadenvik
Journal:  Nat Med       Date:  2003-08-24       Impact factor: 53.440

View more
  5 in total

1.  Serum B-Cell Maturation Antigen (BCMA) Levels Differentiate Primary Antibody Deficiencies.

Authors:  Paul J Maglione; Huaibin M Ko; Minami Tokuyama; Gavin Gyimesi; Camilia Soof; Mingjie Li; Eric Sanchez; Haiming Chen; Lin Radigan; James Berenson; Charlotte Cunningham-Rundles
Journal:  J Allergy Clin Immunol Pract       Date:  2019-08-17

Review 2.  The Extensive Regulation of MicroRNA in Immune Thrombocytopenia.

Authors:  Yuerong Zhao; Siyuan Cui; Yan Wang; Ruirong Xu
Journal:  Clin Appl Thromb Hemost       Date:  2022 Jan-Dec       Impact factor: 3.512

3.  Atypical phenotype and response of B cells in patients with seropositive rheumatoid arthritis.

Authors:  H Rincón-Arévalo; M Rojas; A Vanegas-García; C Muñoz-Vahos; J Orejuela-Erazo; G Vásquez; D Castaño
Journal:  Clin Exp Immunol       Date:  2021-03-02       Impact factor: 4.330

4.  Widespread B cell perturbations in HIV-1 infection afflict naive and marginal zone B cells.

Authors:  Thomas Liechti; Claus Kadelka; Dominique L Braun; Herbert Kuster; Jürg Böni; Melissa Robbiani; Huldrych F Günthard; Alexandra Trkola
Journal:  J Exp Med       Date:  2019-06-20       Impact factor: 14.307

5.  Reversing Autoimmunity Combination of Rituximab and Intravenous Immunoglobulin.

Authors:  A Razzaque Ahmed; Srinivas Kaveri
Journal:  Front Immunol       Date:  2018-07-18       Impact factor: 7.561

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.